Pharmaceutical manufacturing of (1S)-1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate in an immediate-release tablet context requires the solid oral dosage form to be compressed from a pre-blend with controlled particle-size distribution and reduced frictional heating. The four acetyl ester groups on the glucitol moiety introduce hydrolytic sensitivity that is most effectively managed when the API is pre-dried in a vacuum tray dryer at 40 °C until loss on drying by USP <731> remains below 1.5% w/w and Karl Fischer moisture by USP <921> remains below 2.0% w/w. Direct compression is selected over wet granulation only when the formulation can be limited to anhydrous excipients: microcrystalline cellulose NF, anhydrous dibasic calcium phosphate, croscarmellose sodium, and a lubricant such as sodium stearyl fumarate. On a rotary tablet press equipped with compaction force sensors and 10 mm round tooling, compression forces between 8 kN and 16 kN are typically evaluated; lower force fails to generate acceptable tablet hardness, while forces above 18 kN increase ejection shear and may initiate localized ester plasticization that appears as punch filming. The resulting tablet hardness is monitored in the range of 6 kp to 10 kp, friability is held at not more than 1.0% per USP <1216>, and disintegration is controlled to not more than 15 min in purified water at 37 °C per USP <701>. Process-scale batch records include in-process sampling after each blender discharge under 21 CFR 211.110; blend uniformity for the low-dose form is assessed with stratified sampling and requires a relative standard deviation of not more than 5% in accordance with USP <905>. Because the tetraacetate has poor aqueous solubility, dissolution testing is conducted using USP <711> Apparatus II at 50 rpm with a dissolution medium containing a surfactant concentration justified by solubility data; the acceptance criterion follows the product-specific Q value and should not be borrowed from unrelated ester prodrug monographs. The manufacturing suite is maintained at 40–60% relative humidity only if the API is preblended in sealed intermediate bulk containers; when the relative humidity exceeds 60%, the blend is pre-dried and compressed within a limited campaign window because open handling accelerates surface hydrolysis at powder-air interfaces.

What limits direct compression of a tetra-O-acetyl glucitol analogue on high-speed rotary presses?

On rotary presses running at turret speeds above 80 rpm, the limiting variable is not chemical instability but powder flow and segregation. Laser diffraction data are generated per USP <429>; the direct compression grade is milled so that D90 does not exceed 250 µm and the span (D90−D10)/D50 is kept below 2.5 to avoid particle-size segregation in the feed frame. Bulk density measured per USP <616> typically falls between 0.35 g/cm³ and 0.60 g/cm³ depending on spray-drying or jet-milling history; low bulk density material below 0.30 g/cm³ has caused insufficient die fill in a 24-station production press equipped with a paddle feed frame. Compressibility is assessed by Heckel analysis at precompression 0.5–2.0 kN and main compression 5–18 kN; yield-pressure values derived from these curves are used to reject lots that require off-target dwell times at high speed. The acetylated glucitol derivative exhibits a tendency toward low powder bed permeability that becomes visible as lower compression void volume, so forced feed paddle speed is matched to turret rotation to avoid venting defects. If a lot is exposed to open storage at 25 °C/60% RH for more than 14 days, surface energy change can be detected by an increase in tablet ejection force and higher friability after compression; this is managed by an upper moisture specification and nitrogen-blanketed storage. Published stability data for this specific tetraacetate configuration are limited, so holding limits are assigned from ester prodrug stability studies performed under ICH Q1A(R2) conditions rather than from unrelated direct compression actives.

Encapsulation of the tetraacetate in hard capsules uses direct powder filling or low-moisture granulate when dosing flexibility is required for phase II clinical supplies and small-volume commercial packaging. The powder blend is filled on an intermittent or continuous motion capsule machine equipped with a dosing disc and 0–5 mm tamping pins; fill weight is controlled within ±3% of target across a 100,000-capsule batch. Hydroxypropyl methylcellulose capsules are specified rather than gelatin capsules when shell moisture content exceeds 5% w/w, because water migration from the shell to the acetylated API accelerates deacetylation at the solid-solid interface. The blend is loaded into the machine only after screening through a 0.8 mm mesh and after capsule machine contact parts have been dried to prevent water droplet transfer. Lubrication with 0.25% w/w sodium stearyl fumarate is preferred over magnesium stearate when long blend residence times are expected in the hopper; the hydrolytic degradation rate of the tetraacetate in a basic salt environment can change over 60 min hold times. Capsule content uniformity is monitored according to USP <905>, and dissolution is performed on the filled capsules using USP <711> Apparatus I or II depending on the development protocol. Fill-equipment relative humidity is limited to not more than 50%, and any blend exposed for longer than 4 h is rejected unless a use test demonstrates that total related substances remain below 0.5% under the specified holding condition. Because capsule fill operations generate less compression heat than tableting, the acetyl protecting groups are not exposed to the same tableting shear; however, capsule shells introduce water and oxygen permeability, so the finished capsule is packaged with a desiccant and is not stored at more than 40 °C/75% RH without container closure system data. Cleaning validation for the capsule contact surfaces follows 21 CFR 211.67, with surface swab limits calculated from the 1/1000th minimum therapeutic dose criterion.

Wet Granulation Endpoint Windows in High-Shear Mixers

Although direct compression and dry granulation are preferred, wet granulation is used when the intended tablet load requires a densified intermediate that can carry 40% w/w active loading without segregation. The granulation vehicle is a non-aqueous or low-water system such as anhydrous isopropanol or a hydroalcoholic mixture containing not more than 10% water, and the process is run in a high-shear mixer with a main impeller tip speed of 6–10 m/s and a side-chopper speed of 1,500–3,000 rpm. The endpoint is defined by power consumption, impeller torque, and granule particle-size growth rather than by time alone; on a 600 L granulator, water addition rate is capped at 0.5 kg/min to prevent local over-wetting, and the spray nozzle is a binary nozzle positioned above the moving powder bed. The wet mass is discharged at a loss on drying of 8–12%, then dried in a fluid-bed dryer with inlet air temperature not exceeding 50 °C because higher temperatures accelerate ester pyrolysis at the granule surface. Drying is terminated when granule moisture falls below 2.0% by USP <921>; over-drying below 0.5% increases friable granule formation and should be avoided to maintain tableting yield. Granule particle-size distribution is measured by sieve analysis per USP <786>, with the target fraction retained between 20 mesh and 80 mesh not less than 65% of the batch. The granulate is then blended with extragranular disintegrant before compression. If the granulation endpoint is missed by over-addition of solvent, the resulting dough can hydrolyze the tetraacetate at the surface, increasing total related substances above 0.5%; therefore the batch is quarantined and tested by HPLC per ICH Q2(R2) before further processing.

Roller compaction is the primary granulation route for the tetraacetate when direct compression is unsuitable due to poor flow and wet granulation is excluded because of hydrolytic degradation. The API is pre-blended with excipients, and hydraulic pressure is applied between counter-rotating rolls. On a production roller compactor with 200 mm diameter rolls, roll force is maintained between 30 kN and 60 kN, roll gap between 1.5 mm and 3.0 mm, and roll speed between 5 rpm and 12 rpm to produce ribbon density of 1.05–1.20 g/cm³. Ribbon density below 1.0 g/cm³ produces excessive fines and tableting capping; ribbon density above 1.25 g/cm³ produces hard granules that resist disintegration. The compacted ribbon is milled through a rotating impeller mill with a 1.0 mm or 1.5 mm screen, and the resulting granules are blended with croscarmellose sodium before compression. In-process controls include sieve analysis per USP <786> and moisture by USP <921>. Because no aqueous binder is used, hydrolytic degradation is confined to ambient moisture; the process is terminated if granule moisture exceeds 2.5% w/w. This route is used for high-dose tablets where 30–50% API loading is needed, and it provides a granule intermediate that can be filled into capsules or compressed into tablets without aqueous processing. Dry granulation is also preferred when the formulation contains water-sensitive co-excipients or when avoiding amine-based additives is required because the acetyl groups can undergo aminolysis in the presence of primary or secondary amines.

When Injectable Presentation Requires pH-Controlled Reconstitution

For an injectable dosage form, the tetraacetate API is processed as a sterile powder or lyophilized intermediate because the acetyl esters undergo measurable hydrolysis in aqueous solution at neutral to basic pH. The sterile powder is produced by aseptic crystallization and micronization, followed by dry heat or gamma irradiation only if validated, because the molecule contains multiple chiral centers and labile ester groups; terminal sterilization by autoclave is generally unsuitable due to hydrolytic degradation above 60 °C in the presence of residual moisture. The powder is filled aseptically into vials under ISO 14644-1 Class A conditions with Class B surrounding, using a 100% in-line checkweigher and foreign particulate inspection. The reconstitution diluent is optimized to a pH between 4.0 and 5.0 to slow ester hydrolysis; if the final injectable solution is prepared outside this pH window, the rate of deacetylation can exceed the specification for unknown related substances defined under ICH Q3B. The filled vial is controlled for particulate matter by USP <788>, with limits of not more than 6,000 particles per container for ≥10 µm and not more than 600 particles per container for ≥25 µm. The diluent system for poorly water-soluble tetraacetate typically requires a co-solvent such as propylene glycol or a surfactant such as polysorbate 80, but the formulation must not be held for more than 4 h at room temperature unless stability data demonstrate that total related substances remain below 0.5%. The injectable form is not administered as an aqueous pre-mixed solution unless the manufacturer has validated a closed, low-pH, nitrogen-sparged filling line. Because published hydrolytic rate constants for this specific acetylated glucitol derivative are limited, formulation decisions for injectable presentation rely on bracketed stability studies under ICH Q1A(R2) and forced degradation conditions; the operational boundaries are therefore set conservatively rather than interpolated from unrelated ester-containing injectable molecules.